title: The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy.
abstract: LDH may represent an indirect marker of neo-angiogenesis and worse prognosis in many tumour types. We assessed the correlation between LDH and clinical outcome for biliary tract cancer (BTC) patients treated with first-line chemotherapy. Overall, 114 advanced BTC patients treated with first-line gemcitabine and cisplatin were included. Patients were divided into two groups (low vs. high LDH), according to pre-treatment LDH values. Patients were also classified according to pre- and post-treatment variation in LDH serum levels (increased vs. decreased). Median progression free survival (PFS) was 5.0 and 2.6 months respectively in patients with low and high pre-treatment LDH levels (p = 0.0042, HR = 0.56, 95% CI: 0.37-0.87). Median overall survival (OS) was 7.7 and 5.6 months (low vs. high LDH) (p = 0.324, HR = 0.81, 95% CI: 0.54-1.24). DCR was 71% vs. 43% (low vs. high LDH) (p = 0.002). In 38 patients with decreased LDH values after treatment, PFS and OS were respectively 6.2 and 12.1 months, whereas in 76 patients with post-treatment increased LDH levels, PFS and OS were respectively 3.0 and 5.1 months (PFS: p = 0.0009; HR = 0.49; 95% IC: 0.33-0.74; OS: p < 0.0001; HR = 0.42; 95% IC: 0.27-0.63). Our data seem to suggest that LDH serum level may predict clinical outcome in BTC patients receiving first-line chemotherapy.
authors.affiliation: Department of Medical Oncology, AOU "Ospedali Riuniti" - Università Politecnica delle Marche, Ancona, Italy.|Medical Oncology, University Hospital, University of Cagliari, Cagliari, Italy.
authors.forename: Luca
authors.initials: L
authors.lastname: Faloppi
authors.affiliation: Department of Medical Oncology, AOU "Ospedali Riuniti" - Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Michela
authors.initials: M
authors.lastname: Del Prete
authors.affiliation: IRCCS, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Meldola, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Casadei Gardini
authors.affiliation: Department of Medical Oncology, Campus Bio-Medico University of Rome, Roma, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Santini
authors.affiliation: Medical Oncology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Silvestris
authors.affiliation: Department of Medical Oncology, AOU "Ospedali Riuniti" - Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Maristella
authors.initials: M
authors.lastname: Bianconi
authors.affiliation: Department of Medical Oncology, AOU "Ospedali Riuniti" - Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Riccardo
authors.initials: R
authors.lastname: Giampieri
authors.affiliation: IRCCS, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Meldola, Italy.
authors.forename: Martina
authors.initials: M
authors.lastname: Valgiusti
authors.affiliation: Medical Oncology Unit, Cancer Institute "Giovanni Paolo II", Bari, Italy.
authors.forename: Oronzo
authors.initials: O
authors.lastname: Brunetti
authors.affiliation: Department of Medical Oncology, AOU "Ospedali Riuniti" - Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Bittoni
authors.affiliation: Department of Medical Oncology, AOU "Ospedali Riuniti" - Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Kalliopi
authors.initials: K
authors.lastname: Andrikou
authors.affiliation: Medical Oncology, University Hospital, University of Cagliari, Cagliari, Italy.
authors.forename: Eleonora
authors.initials: E
authors.lastname: Lai
authors.affiliation: Medical Oncology, University Hospital, University of Cagliari, Cagliari, Italy.
authors.forename: Alessandra
authors.initials: A
authors.lastname: Dessì
authors.affiliation: Department of Medical Oncology, AOU "Ospedali Riuniti" - Università Politecnica delle Marche, Ancona, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Cascinu
authors.affiliation: Medical Oncology, University Hospital, University of Cagliari, Cagliari, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Scartozzi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001661:Biliary Tract Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D014408:Biomarkers, Tumor / Q000097:blood; D002945:Cisplatin / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012372:ROC Curve; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D003841:Deoxycytidine; D007770:L-Lactate Dehydrogenase; D002945:Cisplatin; D000093542:Gemcitabine